Clinical Trial Update: Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) [Phase 2]

View source ↗

Summary

A phase 2 clinical trial update for anlotinib in small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED